Search by Drug Name or NDC

    NDC 00024-5871-01 TOUJEO Max 300 U/mL Details

    TOUJEO Max 300 U/mL

    TOUJEO Max is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sanofi-Aventis U.S. LLC. The primary component is INSULIN GLARGINE.

    Product Information

    NDC 00024-5871
    Product ID 0024-5871_23d7263b-16d4-4b17-bc45-8e499861015d
    Associated GPIs 2710400300D236
    GCN Sequence Number 078265
    GCN Sequence Number Description insulin glargine,hum.rec.anlog INSULN PEN 300/ML (3) SUBCUT
    HIC3 C4G
    HIC3 Description INSULINS
    GCN 44561
    HICL Sequence Number 022025
    HICL Sequence Number Description INSULIN GLARGINE,HUMAN RECOMBINANT ANALOG
    Brand/Generic Brand
    Proprietary Name TOUJEO Max
    Proprietary Name Suffix n/a
    Non-Proprietary Name insulin glargine
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 300
    Active Ingredient Units U/mL
    Substance Name INSULIN GLARGINE
    Labeler Name Sanofi-Aventis U.S. LLC
    Pharmaceutical Class Insulin Analog [EPC], Insulin [CS]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA206538
    Listing Certified Through 2024-12-31

    Package

    NDC 00024-5871-01 (00024587101)

    NDC Package Code 0024-5871-01
    Billing NDC 00024587101
    Package 1 SYRINGE in 1 CARTON (0024-5871-01) / 3 mL in 1 SYRINGE
    Marketing Start Date 2018-03-26
    NDC Exclude Flag N
    Pricing Information N/A